Author

D. Cianferoni

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

A. Ganez Zapater· 1 shared A. Miro Canturri· 1 shared C. Cannata· 1 shared D. Datta· 1 shared J. Arribas· 1 shared J. Querol· 1 shared L. Espinar· 1 shared L. Pascual-Reguant· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Ganez Zapater

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

The BRD4S-LOXL2-MED1 interaction at the forefront of cell cycle transcriptional control in triple-negative breast cancer

L. Pascual-Reguant, T. V. Tian, D. Datta, D. Cianferoni, S. Kourtis, A. Ganez Zapater, C. Cannata, Q. Serra Camprubi, L. Espinar, M. Guirola, J. Querol, A. Miro Canturri, J. Arribas, L. Serrano, S. Peiro, S. Sdelci

This study shows that inhibiting LOXL2 and BRD4 together reduces triple-negative breast cancer proliferation by disrupting the BRD4S-LOXL2-MED1 interaction that controls cell cycle gene expression.

bioRxiv · May 27, 2022 · PreprintCancer Biology